- Home
- APLT vs ICHR Comparison
APLT vs ICHR Comparison
Compare APLT & ICHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- ICHR
- Stock Information
- Founded
- APLT 2016
- ICHR 1999
- Country
- APLT United States
- ICHR United States
- Employees
- APLT N/A
- ICHR N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- ICHR Semiconductors
- Sector
- APLT Health Care
- ICHR Technology
- Exchange
- APLT Nasdaq
- ICHR Nasdaq
- Market Cap
- APLT 128.0M
- ICHR 999.2M
- IPO Year
- APLT 2019
- ICHR 2016
- Fundamental
- Price
- APLT $0.90
- ICHR $32.29
- Analyst Decision
- APLT Buy
- ICHR Strong Buy
- Analyst Count
- APLT 7
- ICHR 8
- Target Price
- APLT $6.10
- ICHR $42.50
- AVG Volume (30 Days)
- APLT 8.4M
- ICHR 229.6K
- Earning Date
- APLT 11-07-2024
- ICHR 02-04-2025
- Dividend Yield
- APLT N/A
- ICHR N/A
- EPS Growth
- APLT N/A
- ICHR N/A
- EPS
- APLT N/A
- ICHR N/A
- Revenue
- APLT N/A
- ICHR $819,230,000.00
- Revenue This Year
- APLT N/A
- ICHR $5.99
- Revenue Next Year
- APLT $2,664.24
- ICHR $15.26
- P/E Ratio
- APLT N/A
- ICHR N/A
- Revenue Growth
- APLT N/A
- ICHR N/A
- 52 Week Low
- APLT $0.77
- ICHR $26.40
- 52 Week High
- APLT $10.62
- ICHR $46.43
- Technical
- Relative Strength Index (RSI)
- APLT 19.46
- ICHR 52.75
- Support Level
- APLT $0.78
- ICHR $30.37
- Resistance Level
- APLT $0.90
- ICHR $32.03
- Average True Range (ATR)
- APLT 0.12
- ICHR 1.45
- MACD
- APLT 0.26
- ICHR -0.03
- Stochastic Oscillator
- APLT 20.97
- ICHR 66.59
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About ICHR Ichor Holdings
Ichor Holdings Ltd is engaged in the design, engineering, and manufacturing of critical fluid delivery subsystems and components for semiconductor capital equipment. The product offerings include gas and chemical delivery subsystems, collectively known as fluid delivery subsystems, which are key elements of the process tools used in the manufacturing of semiconductor devices. The company also manufactures machined components, weldments, and proprietary products for use in fluid delivery systems. Geographically, the company operates in the United States, the United Kingdom, Singapore, Malaysia, Korea, and Mexico, of which a majority of the revenue is generated from Singapore.